PolyPeptide Group AG
SIX:PPGN
PolyPeptide Group AG
PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. The company is headquartered in Zug, Zug and currently employs 1,041 full-time employees. The company went IPO on 2021-04-29.
PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. The company is headquartered in Zug, Zug and currently employs 1,041 full-time employees. The company went IPO on 2021-04-29.
Core Growth: PolyPeptide's core business achieved strong underlying revenue growth in the first half, fully offsetting lost COVID-related sales.
Profitability Decline: Profitability dropped sharply, mainly due to one-off inventory write-offs and negative cost absorption linked to inventory optimization.
Operational Improvement: The operational improvement plan is about halfway complete, with visible progress but further work ahead to boost productivity.
Second Half Outlook: Management expects both revenue and EBITDA to be higher in the second half compared to the first, though a full-year net loss is anticipated.
Financing & CapEx: The company is in advanced talks for new financing to support working capital and increased CapEx, with no plans for an equity raise.
Customer Engagement: Customer relationships remain strong, pipeline projects have grown, and key partnerships, especially in metabolics (GLP-1), are advancing.
